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Asthma is a common inflammatory disease of airways that is often associated with type 2 responses triggered by allergens, such as house dust mites (HDMs). IL-25 is a key mucosal cytokine that may be produced by stressed epithelial cells; it rapidly activates type 2 innate lymphoid cells to produce IL-13 and IL-5. When administered directly into lungs, IL-25 induces acute inflammation. However, the mechanisms underlying IL-25-initiated inflammation and the roles of this cytokine in the context of HDM-induced allergic inflammation are not fully understood. We show in this article that lung-resident conventional dendritic cells were direct targets of IL-25. IL-25-stimulated dendritic cells rapidly induced mediators, such as the chemokine CCL17, which, in turn, attracted IL-9-producing T cells. Importantly, these mechanisms also operated during HDM-induced allergic lung inflammation. The Journal of Immunology, 2015, 195: 3525-3529. A sthma is a chronic inflammatory disease of lungs that can be acutely incited by allergens, among other insults. These triggers induce inflammatory mediators, such as IL-25, IL-33, and/or TSLP, cytokines that tend to skew responses toward type 2 (1). IL-25 (IL-17E) is a member of the IL-17 family of cytokines. Elevated levels of IL-25 were correlated with poorly controlled asthma in patients (2, 3) , and IL-25 contributes to allergen-induced allergic asthmalike inflammation in mice (4) . Recently, IL-25 was implicated in rhinovirus-induced exacerbation of allergic lung inflammation in patients and mouse models (5) .
Mucosal epithelial cells produce IL-25 upon encounter with helminths, certain viruses, and allergens (1, 5) . Repeated exogenous pulmonary instillation of IL-25 is sufficient to cause an acute allergic asthma-like inflammation, in part due to rapid production of the type 2 cytokines IL-13 and IL-5 by type 2 innate lymphoid cells (ILC2s) (6, 7) . IL-25 may also target a poorly defined multipotential myeloid precursor cell population (6) , as well as Th9 and some NKT cells (8, 9) .
In addition to IL-13 and IL-5, ILC2s may transiently produce IL-9 after encounter with IL-25 (10, 11) . IL-9 is the signature cytokine of Th9 cells, and it also has been implicated in human asthma and allergen-induced lung inflammation in mice. Exposure to house dust mites (HDMs) for 1 wk leads to the appearance of IL-9-producing T cells, prior to the arrival of Th2 cells (12, 13) . IL-9 may help to initiate and/or amplify type 2 responses at mucosal sites, such as postinfection with Nippostrongylus brasiliensis; it may promote accumulation of basophils and act as a growth and survival factor for mast cells and ILC2s (10, 11, 13, 14) .
IL-25 is the only member of the IL-17 cytokine family associated with type 2 responses. It signals via a heteromeric receptor (common IL-17RA and proprietary IL-17RB) and the adaptor protein CIKS (Act1, Traf3ip2), which is also required for signaling by other IL-17 cytokines (15) . Mice lacking this adaptor no longer respond to instillation of IL-25 into lungs (16, 17) .
Despite much recent progress, it remains poorly understood how IL-25 initiates allergic lung inflammation and how it contributes in the context of allergen-induced inflammation. In this article, we show that IL-25 targeted lung dendritic cells (DCs) to induce mediators, such as the chemokine CCL17, which was critical for rapid accumulation of IL-9-producing T cells. We further demonstrate that, in an acute model of HDM-induced pulmonary inflammation, IL-9 production by T cells was also dependent on IL-25 signaling into DCs. 
Materials and Methods

Mice
Experimentally induced airway inflammation
Age-matched mice were anesthetized with isoflurane and challenged via intranasal (i.n.) inhalation of 25 ml PBS containing 1 mg rIL-25/mouse in single-dose challenges or 25 ml containing 500 ng/dose when challenged on three consecutive days (R&D Systems, Minneapolis, MN); PBS solvent was used in control inhalations. Alternatively, mice were challenged i.n. on days 0, 3, and 6 with 30 mg/dose of HDMs in saline (Greer Laboratories) or salineonly for control inhalations.
Isolation of lung parenchymal cells
Mice were anesthetized with tribromoethanol and exsanguinated, tracheae were exposed, and lungs were lavaged with 0.5 ml PBS. Lungs were perfused with PBS, and 1 ml Liberase DH:DNase I (0.25:0.1 mg/ml; Roche) was instilled through the trachea. Lung tissue was homogenized with gentleMACS (Miltenyi Biotec), following the manufacturer's protocol. Cells were lysed with ACK to remove erythrocytes, passed through a 100-mm strainer, and centrifuged at 300 3 g for 5 min. Single-cell suspensions were stained for flow cytometric analysis (see below). Alternatively, subpopulations were isolated with autoMACS Pro based on the expression of CD11c, CD11b, MHC class II, CD207, CD4, and/or CD45 (Miltenyi Biotec), following the manufacturer's instructions. Sorted cells were used for RNA analysis or stained for flow cytometric analysis. 
Flow cytometric analysis
RT-PCR
RNA was extracted from whole lung tissue or sorted cells by the addition of 1 ml TRIzol (Invitrogen). RNA was purified from supernatant in 70% EtOH with RNeasy, and cDNA was synthesized with QuantiTect (QIAGEN). Gene expression was quantified with a TaqMan kit (Applied Biosystems).
ELISA assays
Levels of IL-9 in bronchoalveolar lavage fluid (BALF) (BioLegend) and CCL17 in lung tissue extracts (R&D System) were determined following the manufacturers' instructions. Protein from the right lung lobule was extracted in 500 ml PBS containing protein inhibitor mixture (Roche Life Science).
Statistical analysis
Comparisons between multiple groups were performed with two-way or oneway ANOVA, with Bonferroni posttest analysis. Comparisons between two groups were performed with two-tailed t tests. All statistical analyses were carried out with GraphPad Prism.
Results and Discussion
IL-25 rapidly induces inflammatory mediators in lung
A single i.n. administration of IL-25, but not PBS, induced the expression of several inflammatory genes in whole lungs within 4 h, as determined with an initial limited PCR array (data not shown). In addition to genes known to be rapidly induced in ILC2s, such as that encoding IL-13 (4), we noted genes not known to originate with ILC2s, such as that encoding the chemokine CCL17 (TARC) (6) . Various cells, in particular DCs, may produce CCL17 (19) . We validated induced expression of Ccl17 with RT-PCR of whole lung tissue; mRNA was induced by 4 h, and a trend emerged by 2 h that was consistent with direct targeting by IL-25 (Fig. 1A) . Stimulated expression was dependent on CIKS, the intracellular adaptor protein required for signaling by IL-25R (Fig. 1B) (16) .
IL-25 directly targets lung-resident DCs
To identify the cell type(s) in which IL-25 induced CCL17, we administered IL-25 or PBS into lungs for 2 and 24 h, bead-sorted lung cells into CD11c + , CD11c 2 CD11b + , and CD11c 2 CD11b 2 fractions, and assessed mRNAs for CCL17, IL-13, IL-5, and IL-9 ( Fig. 2A) . IL-25 failed to induce expression of these genes in CD11c
2 CD11b + cells (includes monocytes, tissue macrophages; data not shown). IL-5, IL-13, and IL-9 mRNAs were induced only in CD11c 2 CD11b 2 cells (includes ILC2s and T cells); expression of IL-5, and especially IL-13, was already increased by 2 h and was prominent by 24 h, whereas that of IL-9 was delayed and only observed by 24 h (not at 4 h either; data not shown). mRNA for CCL17 was induced exclusively in CD11c + cells, starting by 2 h and clearly upregulated by 24 h. We confirmed that ILC2s were the source of IL-5 and IL-13 in these experiments (data not shown), as reported previously (20) . Both ILC2s and CD4 + TCRb + T cells produced IL-9 by 24 h after a single dose of IL-25 (Fig. 2B) . Induced expression of IL-9 in T cells required IL-25R in these cells (Supplemental Fig. 2A) , consistent with the ability of IL-25 to induce IL-9 expression in Th9-polarized cells (9) . The IL-9-producing T cells observed were most likely innate or previously differentiated Th9 cells, given their rapid appearance after IL-25 challenge.
We confirmed CCL17 as a direct target of IL-25 in CD11c + cells, because IL-25-induced expression was largely abrogated in mice conditionally ablated of CIKS in these cells via CD11c-Cre (CD11c D CIKS mice) (Fig. 2C) . Under homeostatic conditions, CD11c + lung cells are composed of alveolar macrophages, resident conventional DCs (cDCs), and a smaller number of monocyte-derived DCs/interstitial macrophages. We ruled out alveolar macrophages and monocyte-derived DCs/macrophages as primary sources, because IL-25 was still able to induce CCL17 in mice conditionally ablated of CIKS in these cells (but not in cDCs) via LysM-Cre (LysM D CIKS) (Fig. 2D) . To provide additional evidence that DCs were the primary source of CCL17, we separated CD11c + cells into MHCII hi and MHCII -/lo fractions. Basal and IL-25-induced expression of CCL17 were confined exclusively to MHCII hi cells (Fig. 2E) . To further characterize the source of CCL17, we made use of reporter mice that carry eGFP in the CCL17 gene locus. As reported (21) , eGFP + cells were already present within the CD11c + population after treatment with PBS; however, the numbers of eGFP + cells increased notably upon treatment with IL-25 (Fig. 2F, left panels) . CCL17-eGFP + cells were roughly equally divided between the two major resident lung cDCs: the CD103 + CD11b 2 and the CD103 2 CD11b + populations (Fig. 2F, right panels) . We also isolated CD207 + and CD207 2 CD11c + cell fractions using beads (CD207 is expressed on CD103 + but not on CD103 2 cDCs in lung) to confirm the IL-25-induced expression of CCL17 in both cDC populations (Fig. 2G) . Finally, we isolated CD11c + cells from CCL17-eGFP reporter mice, stimulated them with IL-25 in vitro, and observed induced expression of eGFP within 24 h (data not shown).
IL-25-induced expression of IL-9 by T cells requires IL-25 signaling into DCs
To assess biologic consequences of IL-25 signaling into DCs, we treated CD11c D CIKS mice and littermate controls with IL-25 (or PBS) on three consecutive days and analyzed inflammatory gene expression 24 h later (Fig. 3A) . CCL17 induction was still largely dependent on IL-25/CIKS-mediated signaling in DCs. Unexpectedly, IL-9 induction was also dependent on such signaling into DCs, even though DCs do not produce this cytokine (see above) (Fig. 3A) . IL-13 and IL-5 mRNA levels were partially reduced in IL-25-treated CD11c D CIKS mice, and these cytokines are not expressed by DCs either (see above). Thus, mediators induced by IL-25 in DCs were required for the production of IL-9 and contributed, in part, to the production of IL-13 and IL-5.
We (Fig. 3B) . Thus, the partial decrease in IL-13 and IL-5 in CD11c D CIKS mice noted above appears to have been due to lower numbers of ILC2s in these mice. We also observed increased numbers of eosinophils and CD4 + TCRb + T cells in WT mice, especially after one additional administration of IL-25; the increase in eosinophils was partially prevented (data not shown) and that in CD4 T cells was largely prevented in CD11c D CIKS mice (Fig. 3C) .
We investigated the cellular source of increased IL-9 production in these experiments. Induced production of IL-9 was seen only in CD4 + TCRb + T cells (not in CD4 (Fig. 3D) . The notion that T cells, and not ILC2s, were the primary source of IL-9 after repeated IL-25 challenges was supported further by analysis of Rag1-deficient (KO) mice. Despite the presence of ILC2s, IL-9 production was notably lower in Rag-KO mice compared with WT mice (Supplemental Fig. 2B ). Additionally, we ruled out NKT cells as a major source of IL-9, because mice lacking NKT cells (CD1d deficient) were able to induce normal levels of IL-9 in response to IL-25 (data not shown). Along with increased numbers of IL-9-producing T cells, we observed increased production of IL-9 and CCL17 proteins in the BALF and total lung tissue, respectively, in WT mice but not in CD11c D CIKS mice (Fig. 3D) . Thus, increased IL-9 production by T cells required IL-25 signaling into DCs.
CCL17 is a chemokine that recruits Th2 and Th9 cells (19, 22) . Therefore, we asked whether CCL17 might play a critical role in the appearance of IL-9-producing T cells in lungs after three challenges with IL-25. The IL-25-induced increases in T cells and IL-9 protein in BALF were largely abrogated in mice deficient in CCL17 (CCL17 KO; Fig. 3E ). Furthermore, IL-25-induced expression of IL-9, but not IL-13 mRNA, was also decreased in CCL17-KO mice. Thus, the early appearance of IL-9-producing T cells largely depended on CCL17, which likely explains the requirement for IL-25 stimulation of DCs. It is possible that additional factors produced by DCs are required. It remains to be determined how IL-25-stimulated DCs contributed to increases in other cell types (Fig. 3B) ; these effects may be mediated directly by DC-produced chemokines/mediators and/or indirectly by onsite production of survival/growth factors, such as IL-9.
IL-25 signaling in DCs promotes IL-9-producing T cells in the context of HDM-induced allergic lung inflammation HDM is composed of multiple biochemical components that activate several potentially redundant inflammatory pathways. To determine whether IL-25, and specifically IL-25 signaling into DCs, might uniquely contribute in the context of the HDM-induced model of asthma, we focused on IL-9 production by T cells as a read-out. We challenged IL-25R-deficient mice (IL-17RB KO) and their littermate controls (WT) i.n. with HDMs or PBS on days 0, 3, and 6 and analyzed lung cells on day 7 for IL-9 expression in CD4 + TCRb + T cells (Fig. 4A) . Although intracellular IL-9 is technically difficult to detect (10, 23) , we observed a significant increase in IL-9 in CD4 + TCRb + (Th9) cells in HDM-over PBS-challenged WT, but not IL-17RB-KO, mice. Thus, IL-25R was critical for accumulation of IL-9-producing T cells in this acute allergen-induced asthma model. To determine whether IL-9 production by T cells also required IL-25 stimulation of DCs, we challenged mice conditionally ablated of IL-17RB in DCs via CD11c-Cre (CD11c D RB) with HDMs, as above. Notably, production of IL-9 protein in T cells (Fig. 4A) and IL-9 mRNA in lungs (Fig. 4B ) was largely abolished in mutant mice. To determine whether CCL17 was critical for the accumulation of IL-9 + T cells in + TCRb + T cell numbers and IL-9 protein levels in BALF and relative expression of Il9 and Il13 in total lung of WT and CCL17-KO mice, challenged as in (A). Data are mean 6 SEM, based on three (A-D) or two (E) independent experiments, with n = 7-9 or n = 6 mice/ genotype/condition, respectively. *p , 0.05, **p , 0.001. the present model, we analyzed CCL17-KO mice. Loss of CCL17 prevented the accumulation of IL-9 + T cells and IL-9 mRNA after HDM treatments (Fig. 4) . Thus, IL-25-mediated signaling into DCs and CCL17 production were important for accumulation of IL-9 + T cells in the acute HDMinduced model of asthma. Therefore, IL-25 stimulation of DCs contributes to lung inflammation not only when initiated by IL-25 itself, but also in the context of HDM-initiated inflammation.
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